Philip J. Rosenfeld, M.D., Ph.D., is a world-renown expert on age-related macular degeneration (AMD) and optical coherence tomography (OCT). He has played a pivotal role in the development of anti-VEGF therapies for neovascular and exudative eye diseases. He revolutionized the treatment of these diseases by pioneering the use of intravitreal Avastin (bevacizumab) therapy, which has prevented blindness worldwide while saving billions of dollars in healthcare expenses. He also introduced the concept of OCT-guided treatment with anti-VEGF therapy. Over the past decade, Rosenfeld has played a pivotal role in the development of the first complement inhibitor for dry AMD known as pegcetacoplan, a C3 complement inhibitor now in Phase 3 clinical trials. He has spent the past 20 years actively involved in the development of clinical OCT instruments and associated imaging algorithms. Research Interest Early-onset and late-onset maculopathies particularly age-related macular degeneration Genetics of AMD Therapies for dry and wet AMD